TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2024-06-04
劉俊人Liu, Chun-Jen
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
-
jiun0924@gmail.com
發表文獻
74筆
21
Tseng TC, Liu CJ, Yang WT, Hsu CY, Hong CM, Su TH, Tsai CH, Chen CL, Yang HC, Liu CH, Chen HH, Chen PJ, Kao JH. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment Pharmacol Ther. 2021 Apr;53(8):908-918. doi: 10.1111/apt.16266. Epub 2021 Jan 19. PMID: 33465271.
22
Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int. 2021 Dec 10. doi: 10.1111/liv.15128. Epub ahead of print. PMID: 34890120.
23
Wu WK, Chen YH, Lee PC, Yang PJ, Chang CC, Liu KL, Hsu CC, Huang CC, Chuang HL, Sheen LY, Liu CJ, Wu MS. Mining Gut Microbiota From Bariatric Surgery for MAFLD. Front Endocrinol (Lausanne). 2021 Apr 9;12:612946. doi: 10.3389/fendo.2021.612946. PMID: 33897617; PMCID: PMC8063105.
24
Liu CH, Peng CY, Kao WY, Yang SS, Shih YL, Lin CL, Tsai MK, Lee CY, Chang CC, Wu JH, Liu CJ, Su TH, Tseng TC, Chen PJ, Kao JH. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. Aliment Pharmacol Ther. 2022 Feb;55(4):434-445. doi: 10.1111/apt.16697. Epub 2021 Nov 13. PMID: 34773272.
25
Huang SC, Cheng PN, Liu CH, Yang HC, Su TH, Tseng TC, Chen PJ, Kao JH, Liu CJ. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. J Formos Med Assoc. 2021 Sep 15:S0929-6646(21)00424-1. doi: 10.1016/j.jfma.2021.09.002. Epub ahead of print. PMID: 34538552.
26
Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc. 2021 Aug 24:S0929-6646(21)00361-2. doi: 10.1016/j.jfma.2021.08.003. Epub ahead of print. PMID: 34452785.
27
Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. Gut Liver. 2021 May 15;15(3):451-458. doi: 10.5009/gnl20218. PMID: 33431715; PMCID: PMC8129653.
28
Yu MW, Lin CL, Liu CJ, Huang YW, Hu JT, Wu WJ, Wu CF. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. J Formos Med Assoc. 2021 Nov 8:S0929-6646(21)00486-1. doi: 10.1016/j.jfma.2021.10.014. Epub ahead of print. PMID: 34764005.
29
Chang HL, Wen WH, Lee CN, Chiu YE, Liu CJ, Chang MH, Lin LH, Chen HL. Kinetics of hepatitis B surface antigen in pregnant women with and without tenofovir disoproxil fumarate. J Viral Hepat. 2022 Feb;29(2):107-114. doi: 10.1111/jvh.13628. Epub 2021 Nov 10. PMID: 34724288.
30
Liu CJ, Chen PJ. Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. Liver Int. 2021 Aug 17. doi: 10.1111/liv.15040. Epub ahead of print. PMID: 34402183.
